Personalized and Precision Medicine 2022
This reprint, guest edited by Anne-Marie Caminade, gives an impressionist overview of the current state of the art about "Personalized and Precision Medicine". Twenty contributions illustrate the diversity of the topic, including new approaches about cancers, neurodegenerative diseases, in...
Saved in:
Other Authors: | |
---|---|
Format: | Electronic Book Chapter |
Language: | English |
Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
Subjects: | |
Online Access: | DOAB: download the publication DOAB: description of the publication |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000naaaa2200000uu 4500 | ||
---|---|---|---|
001 | doab_20_500_12854_98923 | ||
005 | 20230405 | ||
003 | oapen | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 20230405s2023 xx |||||o ||| 0|eng d | ||
020 | |a books978-3-0365-7044-0 | ||
020 | |a 9783036570457 | ||
020 | |a 9783036570440 | ||
040 | |a oapen |c oapen | ||
024 | 7 | |a 10.3390/books978-3-0365-7044-0 |c doi | |
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a M |2 bicssc | |
100 | 1 | |a Caminade, Anne-Marie |4 edt | |
700 | 1 | |a Caminade, Anne-Marie |4 oth | |
245 | 1 | 0 | |a Personalized and Precision Medicine 2022 |
260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
300 | |a 1 electronic resource (286 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
520 | |a This reprint, guest edited by Anne-Marie Caminade, gives an impressionist overview of the current state of the art about "Personalized and Precision Medicine". Twenty contributions illustrate the diversity of the topic, including new approaches about cancers, neurodegenerative diseases, infectious diseases, lungs obstruction, skeletal diseases, intestinal microbiomes, new tools such as ultra-high-frequency ultrasound or non-oncological radiotherapy, and a new class of drugs (dendrimers). This reprint is an illustration of the present and future impact of Personalized and Precision Medicine on all the therapeutic domains. | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Medicine |2 bicssc | |
653 | |a cancer treatment | ||
653 | |a immune checkpoint blockade | ||
653 | |a PD-(L)1 inhibitors | ||
653 | |a interorganizational transaction | ||
653 | |a combination therapy | ||
653 | |a bacteremia | ||
653 | |a carbapenemase | ||
653 | |a carbapenem-resistant Enterobacteriaceae | ||
653 | |a Klebsiella pneumoniae | ||
653 | |a mortality | ||
653 | |a risk factors | ||
653 | |a bone-anchored maxillary protraction | ||
653 | |a skeletal class III malocclusion | ||
653 | |a 3D printing | ||
653 | |a growth modification | ||
653 | |a cancer | ||
653 | |a mucormycosis | ||
653 | |a COVID-19 | ||
653 | |a COVID-associated mucormycosis | ||
653 | |a diabetes | ||
653 | |a steroids | ||
653 | |a immunosuppression | ||
653 | |a dendrimers | ||
653 | |a clinical trials | ||
653 | |a phases 1, 2, and 3 | ||
653 | |a polylysine | ||
653 | |a polyamidoamine | ||
653 | |a TPMT genotype | ||
653 | |a TPMT poor metabolizers | ||
653 | |a TPMT intermediate metabolizers | ||
653 | |a AZA | ||
653 | |a hepatotoxicity | ||
653 | |a cumulative incidence of hepatotoxicity | ||
653 | |a pharmacogenomics | ||
653 | |a autoimmune disease | ||
653 | |a preemptive genotyping | ||
653 | |a TPMI | ||
653 | |a black elderberry | ||
653 | |a polyphenols | ||
653 | |a prebiotic | ||
653 | |a microbiota | ||
653 | |a heart rate variability | ||
653 | |a autonomic nervous system | ||
653 | |a sleep | ||
653 | |a obstructive sleep apnea | ||
653 | |a radiotherapy | ||
653 | |a non-malignant disorders | ||
653 | |a non-oncological radiotherapy | ||
653 | |a electromyography | ||
653 | |a kinematic | ||
653 | |a kinetic | ||
653 | |a low back pain | ||
653 | |a lumbar belt | ||
653 | |a sit-to-stand | ||
653 | |a chronic obstructive pulmonary disease | ||
653 | |a overlap syndrome | ||
653 | |a vitamin D | ||
653 | |a ultrasound | ||
653 | |a ultra-high frequency | ||
653 | |a musculoskeletal | ||
653 | |a imaging | ||
653 | |a urinary bladder neoplasms | ||
653 | |a neoadjuvant therapy | ||
653 | |a cystectomy | ||
653 | |a clinical decision rules | ||
653 | |a prognosis | ||
653 | |a multiple sclerosis | ||
653 | |a personalized medicine | ||
653 | |a autoimmune | ||
653 | |a comorbidities | ||
653 | |a hallmarks of cancer | ||
653 | |a differential interactome | ||
653 | |a system biomarkers | ||
653 | |a druggability | ||
653 | |a personalized treatments | ||
653 | |a total knee arthroplasty | ||
653 | |a fast track rehabilitation | ||
653 | |a inpatient rehabilitation | ||
653 | |a postoperative rehabilitation | ||
653 | |a patient reported outcome measures | ||
653 | |a Huntington's disease | ||
653 | |a psychosocial effects | ||
653 | |a underserved region | ||
653 | |a disease burden | ||
653 | |a genetic counselling | ||
653 | |a genetic testing | ||
653 | |a complications | ||
653 | |a low-molecular-weight heparin | ||
653 | |a thromboembolism | ||
653 | |a cerebral palsy | ||
653 | |a muscle spasticity | ||
653 | |a primary cell culture | ||
653 | |a satellite cells | ||
653 | |a skeletal muscle | ||
653 | |a muscle | ||
653 | |a skeletal | ||
653 | |a humans | ||
653 | |a epigenomics | ||
653 | |a DNA methylation | ||
653 | |a regulatory non-coding RNAs | ||
653 | |a Alzheimer's disease | ||
653 | |a logopenic variant primary progressive aphasia | ||
653 | |a empathy | ||
653 | |a n/a | ||
856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/6976 |7 0 |z DOAB: download the publication |
856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/98923 |7 0 |z DOAB: description of the publication |